Tolerance of Fentanyl Pectin Nasal Spray for Procedural Pain in Geriatric Patients

• Published in: Journal of the American Medical Directors Association Vol. 23; no. 6; p. 1005
• Main Authors: Maljean, Laurentine, Gavazzi, Gaëtan, Gibert, Prudence, Grevy, Armance, Payen, Marion, Zerhouni, Nabil, Tiffet, Théophile, Cracowski, Jean-Luc, Mitha, Nathalie, Maindet, Caroline, Baudrant, Magalie, Bedouch, Pierrick, Drevet, Sabine
• Format: Journal Article
• Language: English
• Published: United States 01.06.2022
• Subjects: Aged; Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Fentanyl; Humans; Nasal Sprays; Neoplasms; Pain, Procedural - chemically induced; Pectins - adverse effects; Pectins - pharmacokinetics; Prospective Studies; Intranasal fentanyl; procedural pain; geriatric patients
• ISSN: 1538-9375
• DOI: 10.1016/j.jamda.2022.03.005

We aimed to assess the tolerance of fentanyl pectin nasal spray (FPNS) when used to treat procedural pain caused by wound dressing or physiotherapy in patients older than 75 years with or without opioid background treatment. This is a prospective monocentric, noncontrolled, nonrandomized study conducted from December 2014 to October 2017 in 2 geriatric wards (rehabilitation and acute medicine). Fifty-seven patients were included and 314 procedures were monitored. For each patient, 6 procedures were monitored: the first 2 without specific treatment, then fentanyl was started at 100 μg with a titration over a few procedures up to 800 μg in non-opioid-naïve patients and 400 μg in opioid-naïve. Sedation and respiratory scale were monitored during the procedures. All adverse drug events occurring from inclusion to 5 days after the intervention were collected and their imputability was assessed separately by 2 pharmacovigilance experts. Overall, 14.4% of the sessions with FPNS administration resulted in adverse drug events. Main adverse drug events were nausea and vomiting, somnolence, and confusion. Most of them were of mild to moderate severity. Four severe adverse events were due to accidental overdoses. No unexpected adverse event occurred. Tolerance was similar for opioid-naïve and non-opioid-naïve patients (P value = .93). FPNS was overall well tolerated in geriatric patients. Given its interesting pharmacokinetics, fentanyl is a promising lead for procedural pain treatment in geriatric patients, even those who are opioid naïve.